Live Biotherapeutic Formulation Using Gene-Specific Microbiome Profiling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for taxonomic profiling of the human microbiome, such as 16S rRNA gene sequencing, fail to describe the gene content and metabolic functions of microbial communities, limiting the understanding of their role in health and disease, and there is a lack of resources for analyzing metagenomic and metatranscriptomic data, hindering the development of live biotherapeutics.
Innovation Solution
Development of a remedial live biotherapeutic formulation comprising Lactobacillus crispatus bacteria configured to express specific asparagine synthase B genes, along with a pharmaceutically acceptable carrier, to address deficiencies or excesses in the vaginal microbial community, targeting conditions like bacterial vaginosis and other vaginal health issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If 16S rRNA gene sequencing is used for taxonomic profiling, then species-level identification is achieved, but gene content and metabolic function information is lost
Solution Approach 1:
The patent segments the microbiome analysis into multiple layers: 16S rRNA gene sequencing for taxonomic identification, and separate metagenomic/metatranscriptomic sequencing for functional analysis. This segmentation allows each method to excel at its specific task while avoiding the information loss that would occur if a single method tried to do everything.
Solution Approach 2:
The patent introduces curated reference databases as intermediaries between raw sequencing data and biological interpretation. These databases contain annotated gene sequences and metabolic pathway information, serving as a bridge that translates metagenomic reads into functional insights without requiring complete de novo assembly.
2Loss of information
If metagenomic and metatranscriptomic datasets are analyzed using de novo assembly, then complete gene content is recovered, but substantial computational resources are required
Solution Approach 1:
The patent employs partial action by using targeted gene mapping instead of complete de novo assembly of all metagenomic data. By mapping reads against curated reference databases containing only relevant bacterial genes, the method recovers sufficient gene content information for biotherapeutic development without the excessive computational burden of assembling entire metagenomes.
Solution Approach 2:
The patent uses copying by creating simplified reference representations of microbial genomes in curated databases. Instead of storing and processing complete raw metagenomic sequences, the method uses annotated gene catalogs that copy essential functional information in a compressed, searchable format, dramatically reducing computational requirements.
3Measurement precision
If curated gene databases are developed for metagenomic analysis, then analysis accuracy improves, but resources for such databases are limited
Solution Approach 1:
The patent creates universally applicable curated databases that serve multiple functions: taxonomic classification, functional annotation, and biotherapeutic strain identification. These multi-functional databases reduce the need for separate specialized resources by integrating diverse information types into unified reference collections.
Solution Approach 2:
The patent merges taxonomic and functional information into integrated curated databases that combine 16S rRNA gene data with metagenomic gene catalogs. This consolidation creates a comprehensive resource that eliminates the need for separate database queries and reduces the total quantity of discrete database resources required.
4Adaptability or versatility
If gene-specific characterizations are performed to identify allelic differences, then probiotic strain selection is improved, but the complexity of microbiome analysis increases
Solution Approach 1:
The patent applies local quality by focusing gene-specific characterizations only on particular genes of interest (such as antibiotic resistance genes or metabolic pathway genes) rather than analyzing entire genomes. This targeted approach improves probiotic strain selection by highlighting functionally relevant allelic differences while keeping analysis complexity manageable through selective rather than comprehensive sequencing.
Data Source
Figure 1
Figure 2~3A
Figure 3B
AI summary
Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.